Mazdutide: What the Evidence Actually Shows

Most of the newly-covered compounds in this content wave are unapproved anywhere. Mazdutide is the exception, and it's worth stating plainly up front rather than burying it: this is an actual approved drug — just not in the United States. Checking its regulatory status live, rather than assuming "investigational" from its category, turned up a more specific and more useful answer than that single word would give you.

What mazdutide actually is

Mazdutide (Innovent Biologics' development code IBI362, Eli Lilly's parallel code LY3305677) is a dual agonist that activates both the GLP-1 receptor and the glucagon receptor at once — the same drug-class category as survodutide, this content wave's other new GLP-1/glucagon dual-agonist article, though the two are separately developed molecules from different companies. It's being developed jointly by Innovent Biologics and Eli Lilly for weight management, type 2 diabetes, and — per ongoing trials — metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnea, and alcohol use disorder¹.

It's already approved — in China

A live PubMed search located a "Drugs: First Approval"-style paper — the standard format Springer's Adis journal publishes for every newly-approved drug worldwide — confirming mazdutide's actual regulatory status. Quoted directly from that paper's own abstract: "In June 2025, mazdutide received its first approval, in China, for use (in combination with diet control and increased physical activity) in long-term body weight management in adults with a body-mass index (BMI) of ≥ 28 kg/m2 or with a BMI ≥ 24 kg/m2 together with one or more weight-related comorbidity. Subsequently, in September 2025, mazdutide also received approval in China for use in glycaemic control in adults with T2D¹." The approved product's brand name in China is Xinermei®¹. Two real regulatory approvals, in the same country, seven months apart, for two different indications — this is not a grey-market product or an unauthorized filing; it is a genuinely approved drug, reviewed by China's regulatory authority.

The pivotal trial behind that approval — real, published, substantial

The trial behind the weight-management approval, GLORY-1, is published in The New England Journal of Medicine: 610 Chinese adults with obesity or overweight, randomized to placebo, 4 mg, or 6 mg mazdutide once weekly by subcutaneous injection. At week 48, mean body-weight change from baseline was -11.00% on the 4 mg dose and -14.01% on the 6 mg dose, against +0.30% on placebo (p<0.001 for all comparisons) — 35.7% and 49.5% of participants respectively achieved at least 15% weight loss, versus 2.0% on placebo². The trial reported "beneficial effects on all prespecified cardiometabolic measures," and adverse events leading to discontinuation were low across all three arms (0.5%-1.5%)². A separate Phase 2 trial specifically testing the higher 9 mg dose in Chinese adults with obesity but without diabetes found an even larger effect: -12.78% weight change versus +1.80% on placebo at 24 weeks³ — real, published, dose-ranging data behind a real approval, not a press-release topline.

Two parallel development tracks — confirmed, not assumed

Here's a detail a search for "mazdutide FDA approval" alone would miss: this molecule is being developed on two separate tracks at once, confirmed directly from each trial's own sponsor field in a live ClinicalTrials.gov search. Innovent Biologics runs the China-focused program under the compound code IBI362 — the molecule that received both 2025 China approvals described above. Eli Lilly separately runs a GLOBAL development track for the same molecule under its own compound codes, LY3305677 and LY900038, including completed Phase 1/2 studies⁴ and an active, currently-recruiting Phase 2 master-protocol trial with a primary completion date of September 2027⁵. That means mazdutide's path toward a U.S. or global approval — separate from the China approval already granted — is real and ongoing, run by a company (Lilly) already experienced in bringing a GLP-1-class drug through FDA review, but it has not concluded, and no U.S. filing timeline has been confirmed in the sources checked for this article.

Zero U.S. presence — confirmed separately, live

None of mazdutide's real China approval changes its status in the United States. A direct query against FDA's own Drugs@FDA database returns a zero-match response for "mazdutide." DailyMed's structured-product-label search, re-confirmed live for this article, returns zero results — no approved U.S. label, and, distinct from that, no grey-market seller has filed a label for a mazdutide-branded product either, unlike retatrutide's ten such filings. There is no legal purchase pathway for mazdutide in the U.S. today, approved or otherwise, and openFDA's FAERS database returns zero reports for "MAZDUTIDE," confirmed live⁶ — consistent with a drug that has no U.S. market presence of any kind to generate a report from.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell mazdutide — this site's own identity-layer research confirms it is not tagged to any reviewed seller, and there is no real vial or grey-market form to check against in the U.S. either. Mazdutide is a genuinely different case from the rest of this content wave: it is a real, approved drug, with real published Phase 3 data behind that approval — just not approved, filed, or legally available in the United States as of this article's live check. If you're comparing GLP-1/glucagon dual-agonist candidates, our Survodutide evidence review covers a close mechanistic relative from a different company that remains unapproved anywhere, and our retatrutide evidence review covers the related triple-agonist candidate with the largest real (if unauthorized) grey-market vial trade of the three.